Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:57:46 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Egetis Therapeutics - Approaching the Final Hurdle

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Egetis Therapeutics - Approaching the Final Hurdle

2021-12-10 10:00:00

Redeye revisits the Egetis Therapeutics’ equity story as the company approaches critical clinical milestones. Thanks to new data confirming the long-term efficacy of Emcitate, we see a high likelihood of the flagship project becoming the first market-approved treatment for MCT8 deficiency. With both this and Aladote in the final stages of clinical development, and multiple inflection points ahead, we see compelling short- and long-term potential in the Egetis stock.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/